Where does the interplay between cholesterol absorption and synthesis in the context of statin and/or ezetimibe treatment stand today?

Atherosclerosis

Volumn 217, Issue 2, 2011, Pages 308-321

  S Descamps, Olivier ^a   De Sutter, Johan ^b   Guillaume, Michel ^c   Missault, Luc ^d  

^a Hospital de Jolimont   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c Cardiology Department   (Belgium)

^d Sint Jan Hospital AV   (Belgium)

Author keywords

Camposterol; Cardiovascular disease; Cholestanol; Cholesterol absorption; Cholesterol synthesis; Coronary heart disease; Delat 8 cholestenol; Desmosterol; Ezetimibe; Lathosterol; LDL cholesterol; Plant sterol; Sitosterol; Statins

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; CAMPESTEROL; CHOLESTANOL; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LATHOSTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SITOSTEROL;

CARDIOVASCULAR DISEASE; CHOLESTEROL ABSORPTION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CORONARY ARTERY DISEASE; DOWN REGULATION; DRUG EFFECT; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; AZETIDINES; CHOLESTEROL; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INTESTINAL ABSORPTION; INTESTINES; LIVER; TREATMENT OUTCOME;

EID: 79960697596     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.06.010     Document Type: Review

References (54)

1. van Himbergen T.M., Matthan N.R., Resteghini N.A., et al. Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J Lipid Res 2009, 50(4):730-739.
2. van Himbergen T.M., Otokozawa S., Matthan N.R., et al. Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway. Arterioscler Thromb Vasc Biol 2010, 30(1):113-120.
3. Thompson G.R., O'Neill F., Seed M. Why some patients respond poorly to statins and how this might be remedied. Eur Heart J 2002, 23(3):200-206.
4. Santosa S., Varady K.A., AbuMweis S., Jones P.J.H. Physiological and therapeutic factors affecting cholesterol metabolism: does a reciprocal relationship between cholesterol absorption and synthesis really exist?. Life Sci 2007, 80(6):505-514.
5. Miserez A.R., Rossi E.A., Keller U. Prediction of the therapeutic response to simvastatin by pretreatment lipid concentrations in 2082 subjects. Eur J Clin Pharmacol 1994, 46(2):107-114.
6. Lahoz C., Pena R., Mostaza J.M., et al. Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment. Metabolism 2005, 54(6):741-747.
7. Leitersdorf E., Eisenberg S., Eliav O., et al. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia. Circulation 1993, 87(4 Suppl):III35-44.
8. Streja L., Packard C.J., Shepherd J., et al. Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol 2002, 90(7):731-736.
9. Packard C.J., Ford I., Robertson M., et al. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 2005, 112(20):3058-3065.
10. Miettinen T.A. Cholesterol production in obesity. Circulation 1974, 44:842-850.
11. Miettinen T.A., Strandberg T.E., Gylling H. Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients. Relation to basal serum cholestanol. Arterioscler Thromb Vasc Biol 2000, 20(5):1340-1346.
12. Miettinen T.A., Kesaniemi Y.A. Cholesterol absorption: regulation of cholesterol synthesis and elimination and within-population variations of serum cholesterol levels. Am J Clin Nutr 1989, 49(4):629-635.
13. Simon J.A., Lin F., Hulley S.B., et al. Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and PHARMACOGENETICS (CAP) Study. Am J Cardiol 2006, 97(6):843-850.
14. Shear C.L., Franklin F.A., Stinnett S., et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins. Circulation 1992, 85(4):1293-1303.
15. Williams M.L., Morris M.T., Ahmad U., et al. Racial differences in compliance with NCEP-II recommendations for secondary prevention at a Veterans Affairs medical center. Ethn Dis 2002, 12(1):S158-S162.
16. Lakoski S.G., Xu F., Vega G.L., et al. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J Clin Endocrinol Metab. 2010, 95(2):800-809.
17. Couture P., Brun L.D., Szots F., et al. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous. Arterioscler Thromb Vasc Biol 1998, 18(6):1007-1012.
18. Hamrefors V., Orho-Melander M., Krauss R.M., et al. A gene score of nine LDL and HDL regulating genes is associated with fluvastatin induced cholesterol changes in women. J Lipid Res 2010, 51(3):625-634.
19. Kajinami K., Akao H., Polisecki E., Schaefer E.J. Pharmacogenomics of statin responsiveness. Am J Cardiol 2005, 96(9A):65K-70K. discussion 34K-35K.
20. Miettinen T.A., Gylling H., Strandberg T., Sarna S. for the Finnish 4S Investigators. Baseline serum cholestanol predicts recurrent coronary events in a subgroup of the Scandinavian Simvastatin Survival Study (4S). BMJ 1998, 316(7138):1127-1130.
21. Morris M.D., Chaikoff I.L., Felts J.M., et al. The origin of serum cholesterol in the rat; diet versus synthesis. J Biol Chem 1957, 224(2):1039-1045.
22. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 1986, 232(4746):34-47.
23. Tilvis R.S., Miettinen T.A. Serum plant sterols and their relation to cholesterol absorption. Am J Clin Nutr 1986, 43:92-97.
24. Vanhanen H.T., Miettinen T.A. Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination. Atherosclerosis 1995, 115:135-146.
25. Glueck C.J., Speirs J., Tracy T., et al. Relationships of serum plant sterols (phytosterols) and cholesterol in 595 hypercholesterolemic subjects, and familial aggregation of phytosterols, cholesterol, and premature coronary heart disease in hyperphytosterolemic probands and their first-degree relatives. Metabolism 1991, 40:842-848.
26. Assmann G., Kannenberg F., Ramey D.R., et al. Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia. Curr Med Res Opin 2008, 24(1):249-259.
27. Miettinen T.A., Tilvis R.S., Kesäniemi Y.A. Serum cholestanol and plant sterol levels in relation to cholesterol metabolism in middle-aged men. Metabolism 1989, 38(2):136-140.
28. Crouse J.R., Grundy S.M. Evaluation of a continuous isotope feeding method for measurement of cholesterol absorption in man. J Lipid Res 1978 Nov, 19(8):967-971.
29. Lee M., Lu K., Patel S.B. Genetic basis of sitosterolemia. Curr Opin Lipidol 2001, 12(2):141-149.
30. Jakulj L., Vissers M.N., Groen A.K., et al. Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial. J Lipid Res 2010, 51(4):755-762.
31. Miettinen T.A., Gylling H. Ineffective decrease of serum cholesterol by simvastatin in a subgroup of hypercholesterolemic coronary patients. Atherosclerosis 2002, 164(1):147-152.
32. Miettinen T.A., Gylling H., Lindbohm N., et al. Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. J Lab Clin Med 2003, 141(2):131-137.
33. Matthan N.R., Resteghini N., Robertson M., et al. J Lipid Res 2010, 51(1):202-209.
34. Miettinen T.A., Gylling H., Lindbohm N., et al. Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. J Lab Clin Med 2003, 141(2):131-137.
35. Gylling H., Miettinen T.A. Baseline intestinal absorption and synthesis of cholesterol regulate its response to hypolipidaemic treatments in coronary patients. Atherosclerosis 2002, 160(2):477-481.
36. Houweling A.H., Vanstone C.A., Trautwein E.A., et al. Baseline plasma plant sterol concentrations do not predict changes in serum lipids, C-reactive protein (CRP) and plasma plant sterols following intake of a plant sterol-enriched food. Eur J Clin Nutr 2009, 63(4):543-551.
37. Pisciotta L., Fasano T., Bellocchio A., et al. Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients. Atherosclerosis 2007, 194(2):e116-e122.
38. Kempen H.J.M., Glatz J.F.C., Gevers Leuven J.A., van der Voort H.A., Katan M.B. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res 1988, 29:1149-1155.
39. Grundy S.M., Ahrens E.H., Davignon J. Synthesis in man. J Lipid Res 1969, 10:304-315.
40. Bhattacharyya A.K., Connor W.E., Spector A.A. Abnormalities of cholesterol turnover in hypercholesterolemic (Type 11) patients. J Lab Clin Med 1976, 88:202-214.
41. Kastelein J.J., Akdim F., Stroes E.S., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358(14):1431-1443.
42. Taylor A.J., Villines T.C., Stanek E.J., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361:2113-2122.
43. Fleg J.L., Mete M., Howard B.V., et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008, 52(25):2198-2205.
44. Meaney A., Ceballos G., Asbun J., et al. The vytorin on carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. J Clin Pharmacol 2009, 49(7):838-847.
45. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9438 patients with chronic kidney disease. Am Heart J 2010, 160(5):785-794. Sharp Collaborative Group.
46. Rossebø A.B., Pedersen T.R., Boman Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359(13):1343-1356.
47. Vanhanen H.T., Miettinen T.A. Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination. Atherosclerosis 1995, 115(2):135-146.
48. Sudhop T., Lutjohann D., Kodal A., et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002, 106(15):1943-1948.
49. Sudhop T., Reber M., Tribble D., et al. Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. J Lipid Res 2009, 50:2117-2123.
50. Turley S.D., Dietschy J.M. Effects of clofibrate, cholestyramine, zanchol, probucol, and AOMA feeding on hepatic and intestinal cholesterol metabolism and on biliary lipid secretion in the rat. J Cardiovasc Pharmacol 1980, 2:281-297.
51. Repa J.J., Turley S.D., Quan G., Dietschy J.M. Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption. J Lipid Res 2005, 46:779-789.
52. Turley S.D. The role of Niemann-Pick C1 - Like 1 (NPC1L1) in intestinal sterol absorption. J Clin Lipidol 2008, 2:S20-S28.
53. Naumann E., Plat J., Mensink R.P. Changes in serum concentrations of noncholesterol sterols and lipoproteins in healthy subjects do not depend on the ratio of plant sterols to stanols in the diet. J Nutr 2003, 133:2741-2747.
54. Escurriol V., Cofán M., Moreno-Iribas C., et al. Phytosterol plasma concentrations and coronary heart disease in the prospective Spanish EPIC cohort. J Lipid Res 2010, 51:618-624.